Provide Trip Sitting & Guiding Services in Every Major City
This list is not meant to be exhaustive. We provide our trip sitting and guiding services in all major cities in Missouri, including those which are not listed below. If we can physically get ourselves to you, we will sit for you. If you are curious whether we are able to service your area specifically, please contact us.
- Kansas City
- St. Louis
- Springfield
- Columbia
- Independence
- Lee's Summit
- O'Fallon
- St. Joseph
- St. Charles
- St. Peters
- Blue Springs
- Florissant
- Joplin
- Chesterfield
- Jefferson City
Substances We Sit With
The one caveat to us being able to provide trip sitting and guiding services is that we cannot provide your substance of choice for personal consumption—we are unable to help with sourcing.
Please understand that psychedelics are still federally controlled substances and you assume all the risk associated with possessing and consuming these medicines.
We are here to facilitate intentional psychedelic experiences where you feel supported along the entire journey—from preparation to sacred ceremonial experience to integration. We facilitate your inner healing by holding a safe, comfortable, non-judgmental space.
- Psilocybin
- Ayahuasca
- Mescaline
- Ketamine
- MDMA/MDA
- Cannabis
- DMT
- LSD
**Psychedelic Passage does not provide psychoactive or controlled substances nor are we licensed therapists, counselors, or medical professionals. We are a harm reduction company offering trip sitting & integration coaching services.**
Psychedelic Reform in Missouri
We are in the midst of a psychedelic renaissance and the legal status of psychedelic substances is evolving rapidly. On February 18, 2021, Representative Michael Davis filed House Bill 1176 which would amend the State’s “right-to-try” law to include psychedelic substances such as MDMA, psilocybin mushrooms, LSD, DMT, ibogaine, and mescaline.
Since 2014, Missouri’s “right-to-try” statute allows terminal patients to access drugs not yet approved by the U.S. Food and Drug Administration (FDA). However, the current policy excludes the use of Schedule I substances, of which most psychedelics are classified.
The bill was referred to the Health and Mental Health Policy Committee in May 2021, where it is still in review. We will continue to update this section as new developments arise.
